Isolation of Candida auris from cystic fibrosis patient, Greece, April 2019

Euro Surveill. 2019 Jul;24(29):1900400. doi: 10.2807/1560-7917.ES.2019.24.29.1900400.

Abstract

We report the first isolation of Candida auris in Greece from a sputum culture of a cystic fibrosis patient in their 20s under posaconazole treatment. The pathogen was identified as C. duobushaemulonii by VITEK2YST, but as C. auris by MALDI-TOF MS. This case underscores the need for species-level identification of all non-albicans Candida (NAC) isolates from cystic fibrosis patients and patients with predisposing factors to fungal infection.

Keywords: Candida auris; Greece; antifungal susceptibility; cystic fibrosis; first isolation.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Antifungal Agents / therapeutic use
  • Candida / drug effects
  • Candida / isolation & purification*
  • Cystic Fibrosis / complications*
  • Cystic Fibrosis / drug therapy
  • Greece
  • Humans
  • Microbial Sensitivity Tests
  • Mycological Typing Techniques / methods*
  • Phylogeny
  • Sequence Analysis, DNA
  • Species Specificity
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods*
  • Sputum / microbiology*
  • Treatment Outcome
  • Triazoles / therapeutic use
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents
  • Triazoles
  • posaconazole